ILLUSTRATED REVIEW

Illustrated State-of-the-Art Capsules of the ISTH 2021 Congress

Sriram Krishnaswamy PhD⁴ | Walter Ageno MD⁵ | Yaseen Arabi MD³ | Tiziano Barbui MD⁴ | Suzanne Canegieter MD, PhD⁵ | Marc Carrier MD, MSc, FRCPC⁶ | Audrey C. Cleuren PhD⁷ | Peter Collins⁸ | Laurence Panicot-Dubois⁹ | Jane E. Freedman MD⁴ | Kathleen Freson PhD¹ | Philip Hogg PhD¹² | Andra H. James MD¹³ | Colin A. Kretz PhD¹⁴ | Michelle Lavin MB, PhD, FRCPath¹⁵,¹⁶ | Frank W. G. Leebeek MD, PhD¹⁷ | Weikai Li PhD¹⁸ | Coen Maas PhD¹⁹ | Kellie Machlus PhD²⁰ | Michael Makris MD²¹ | Ida Martinelli MD, PhD²² | Leonid Medved PhD²³ | Marguerite Neerman-Arbez PhD²⁴ | James S. O'Donnell PhD²⁵,²⁶,²⁷ | Jamie O'Sullivan PhD²⁸ | Madhvi Rajpurkar MD²⁹,³⁰ | Verena Schroeder PhD³¹ | Paul Clinton Spiegel Jr PhD³² | Simon J. Stanworth MD³³,³⁴,³⁵ | Laura Green MD³⁶,³⁷ | Anetta Undas MD, PhD³⁸

¹Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
²University of Insurbia, Varese, Italy
³King Abdulaziz Medical City, Ministry of NGHA, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
⁴Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
⁵Departments of Clinical Epidemiology and Thrombosis & Haemostasis, Leiden University Medical Center, Leiden, The Netherlands
⁶Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
⁷Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA
⁸School of Medicine Cardiff University, Haemophilia Centre, University Hospital of Wales, Cardiff, UK
⁹Faculty of Pharmace, AMU C2VN INSERM 1263, Marseille, France
¹⁰Vanderbilt University Medical Center, The Albert Sherman Center, Worcester, MA, USA
¹¹Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium
¹²Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
¹³Duke University, Durham, NC, USA
¹⁴TaARI, McMaster University, Hamilton, ON, Canada
¹⁵National Coagulation Centre, St. James's Hospital, Dublin, Ireland
¹⁶Irish Centre for Vascular Biology, RCSI, Dublin, Ireland
¹⁷Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
¹⁸Washington University in St. Louis Medical School, St. Louis, MO, USA
¹⁹University Medical Center Utrecht, Utrecht, The Netherlands
²⁰Vascular Biology Program and Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
²¹University of Sheffield, Sheffield, UK
²²Hemophilia and Thrombosis Center, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Abstract

This year’s Congress of the International Society of Thrombosis and Haemostasis (ISTH) was hosted virtually from Philadelphia July 17–21, 2021. The conference, now held annually, highlighted cutting-edge advances in basic, population and clinical sciences of relevance to the Society. Despite being held virtually, the 2021 congress was of the same scope and quality as an annual meeting held in person. An added feature of the program is that talks streamed at the designated times will then be available online for asynchronous viewing. The program included 77 State of the Art (SOA) talks, thematically grouped in 28 sessions, given by internationally recognized leaders in the field. The SOA speakers were invited to prepare brief illustrated reviews of their talks that were peer reviewed and are included in this article. The topics, across the main scientific themes of the congress, include Arterial Thromboembolism, Coagulation and Natural Anticoagulants, COVID-19 and Coagulation, Diagnostics and Omics, Fibrinogen, Fibrinolysis and Proteolysis, Hemophilia and Rare Bleeding Disorders, Hemostasis in Cancer, Inflammation and Immunity, Pediatrics, Platelet Disorders, von Willebrand Disease and Thrombotic Angiopathies, Platelets and Megakaryocytes, Vascular Biology, Venous Thromboembolism and Women’s Health. These illustrated capsules highlight the major scientific advances with potential to impact clinical practice. Readers are invited to take advantage of the excellent educational resource provided by these illustrated capsules. They are also encouraged to use the image in social media to draw attention to the high quality and impact of the science presented at the congress.
## CONTENTS

| Author(s)                        | Title                                                                 |
|---------------------------------|----------------------------------------------------------------------|
| Walter Ageno                    | Splanchnic vein thrombosis                                            |
| Yaseen Arabi                    | Venous thromboprophylaxis in the ICU                                  |
| Tiziano Barbui                  | Myeloproliferative neoplasm-associated thrombosis                      |
| Suzanne Cannegieter            | VTE risk in premenopausal women: Questions still unanswered           |
| Marc Carrier                    | Primary thromboprophylaxis: Who, what, and how?                       |
| Audrey C. Cleuren              | Molecular analysis of vascular gene expression                        |
| Peter Collins                  | Hemostatic management of postpartum hemorrhage                        |
| Laurence Panicot-Dubois         | Mechanistic insights from 3-D visualization of thrombus formation in cancer |
| Jane E. Freedman               | Platelets: Influenza and other viral responses                        |
| Kathleen Freson                | Hemostatic phenotypes and genetic disorders                           |
| Philip Hogg                    | Functional disulfide bonds in hemostasis and thrombosis               |
| Andra H. James                 | Disparities in pregnancy outcomes: Differences by condition and community |
| Colin A. Kretz                 | Specificity of adamts13 and regulation of adamts13 function           |
| Michelle Lavin                 | Pregnancy, postpartum and periods: Current challenges in the management of women with VWD |
| Frank W.G. Leebeek             | The impact of aging and inflammation on plasma VWF levels             |
| Weikai Li                      | Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation |
| Coen Maas                      | Pathogenic factor XII mutations: Form determines dysfunction          |
| Kellie Machlus                 | Platelet vesicles communicate with the bone marrow during inflammation |
| Michael Makris                 | Current and future haemophilia treatment options: Clinician perspective |
| Ida Martinelli                 | Cerebral venous sinus thrombosis                                      |
| Leonid Medved                  | Fibrinogen-endothelial cell interactions in inflammation             |
| Marguerite Neerman-Arbez       | Fibrinogen in human disease                                           |
| James S. O’Donnell             | VWF modulates adhesion of malaria-infected erythrocytes to endothelial cells |
| Jamie O’Sullivan               | Von Willebrand Factor (VWF) structure-function in the regulation of cancer metastasis |
| Madhvi Rajpurkar               | Pulmonary embolism in children                                        |
| Verena Schroeder               | Intermolecular interactions that stabilize multimeric FXIII           |
| Paul Clinton Spiegel           | Factor VIII structure: Determinants of inhibitor development          |
| Simon J. Stanworth and Laura Green | Do platelet transfusions work?                                    |
| Anetta Undas                   | Prothrombotic fibrin clot properties and vascular diseases            |
Anticoagulant Therapy for Splanchnic Vein Thrombosis: Summary of Suggested Treatment Strategies

(Adapted from Di Nisio et al JTH 2020)

Cirrhotic patients
- Initial management: Therapeutic dose LMWH
- Primary treatment: Switch to VKAs or DOACs (depending on severity of liver dysfunction)
- Remarks: Consider early variceal screening and prophylaxis of high-risk varices
- Duration: at least 3 to 6 months, consider indefinite if bleeding risk acceptable

Cancer patients
- Initial management and primary treatment: LMWH or DOACs.
- Remarks: LMWH first choice in patients with endoluminal gastrointestinal cancer or genitourinary cancer at high bleeding risk. Apixaban possible alternative for primary treatment
- Duration: at least 3 to 6 months. Consider indefinite if active cancer and low bleeding risk

Other patients
- Initial management and primary treatment: DOACs
- Remarks: LMWH and VKAs if contraindications to or unavailability of DOACs. DOACs are not specifically approved for splanchnic vein thrombosis
- Duration: 3 to 6 months. Consider indefinite if unprovoked or persistent risk factors and low bleeding risk

For references, see Di Nisio et al.¹
Venous thromboprophylaxis in the intensive care unit

Yaseen Arabi MD

Prevention of venous thromboembolism in critically ill patients involves multi-modality approach. A systematic review of randomized controlled trials (RCTs) demonstrated that early mobilization in critically ill patients was associated with a significant reduction in deep vein thrombosis (DVT) (RR 0.16, 95% CI 0.06, 0.47). Avoidance of unnecessary use of central venous catheters, especially in the femoral vein, is an important aspect of DVT preventive strategy. One RCT found that subclavian compared to femoral venous catheterization in critically ill patients was associated with a significant reduction in catheter-related thrombosis documented by ultrasonographic examination (RR 0.09, 95% CI 0.02, 0.36). Pharmacologic thromboprophylaxis with unfractionated or low-molecular-weight heparin, compared to no thromboprophylaxis, also reduces the incidence of DVT (RR 0.51, 95% CI 0.41, 0.63). Data on the effectiveness of pneumatic review that included observational studies demonstrated lower DVT with intermittent pneumatic compression (RR 0.34, 95% CI 0.19, 0.60).
Myeloproliferative neoplasm-associated thrombosis

Tiziano Barbui

For references, see Barbui et al., Tefferi et al., and De Stefano et al.
Venous thrombo-embolism; risk in premenopausal women: Questions still unanswered

Suzanne Cannegieter MD PhD

VTE: Venous thrombo-embolism; PCOS: Polycystic ovary syndrome
For references, see Samuelsson et al,9 Scheres et al,10 and Roach et al.11
Venous thromboembolism (VTE) is associated with significant morbidity, mortality and healthcare utilization among ambulatory patients with cancer initiating systemic chemotherapy. Direct oral anticoagulants and low molecular weight heparins have been shown to be safe and effective to prevent cancer-associated thrombosis in this patient population.\textsuperscript{12} Hence, the use of primary thromboprophylaxis should be considered to decrease the risk of VTE and tailored to minimize the risk of bleeding.\textsuperscript{12} Patients should be educated about signs and symptoms of cancer-associated thrombosis and stratified according to their underlying risk of VTE and bleeding for potential consideration of primary thromboprophylaxis. Multidisciplinary approaches (nurses, pharmacists and physicians) are successful models for primary thromboprophylaxis implementation in ambulatory patients with cancer initiating systemic chemotherapy.\textsuperscript{13}

DOAC: Direct oral anticoagulants; KS: Khorana Score; LMWH: Low molecular weight heparin; VTE: Venous thromboembolism.
Molecular analysis of vascular gene expression

Audrey C. Cleuren

Vascular heterogeneity, particularly in the endothelial cell (EC) compartment, has long been recognized yet difficult to study given the poor accessibility of these cells. (A) The Ribotag mouse model\textsuperscript{14} enables evaluation of gene expression profiles directly in vivo in a cell-specific manner via translating ribosome affinity purification (TRAP). (B) EC-TRAP combined with high-throughput RNA sequencing provides an accurate in vivo snapshot of organ-specific endothelial gene expression programs. In addition to the extensive EC heterogeneity across organs under physiologic conditions shown here, our data also showed vascular bed-specific EC reactivity after lipopolysaccharide-induced endotoxemia (ref\textsuperscript{15}).
Postpartum hemorrhage (PPH) is caused by obstetric complications but may be exacerbated by impaired hemostasis. Hypofibrinogenemia is the commonest coagulopathy associated with PPH and occurs early in abruptions and amniotic fluid embolism. Depletion of other coagulation factors, thrombin generation and platelets is uncommon until large bleeds have occurred.

Early hypofibrinogenemia predicts progression to severe hemorrhage, however, laboratory Clauss fibrinogen is usually too slow to be clinically useful during rapid bleeding. Point-of-care viscoelastometric hemostatic assays (VHA) allow surrogate measurement of fibrinogen and predict severe outcomes. A double blind RCT showed that fibrinogen >2 g/L is adequate for hemostasis during PPH.

An all Wales quality improvement programme involving 60,000 deliveries combined accurate measurement of blood loss with VHAs to guide early fibrinogen replacement. It was associated with reduced massive PPH (≥ 2500 ml) by 23%, decreased red cell and FFP transfusion by 22% and 58%, respectively and reduced severe anemia (Hb <80 g/L) by 33%.
Mechanistic insights from 3-D visualization of thrombus formation in cancer

Laurence Panicot-Dubois

For references, see Carminita et al. and Palacios-Acedo et al.
Growing mechanistic and clinical data demonstrate that platelets perform various immune functions during infection. A platelet can form heterotypic aggregates with various types of immune cells including monocytes, neutrophils, eosinophils, and dendritic cells. Platelets participate in innate and adaptive immunity and act as immune cells during viral infections. Platelets may internalize ssRNA viruses including influenza, HIV, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and encephalomyocarditis. For some viruses, this internalization leads to lysosomal degradation of the viral coat and activation of the pathogen-associated molecular pattern receptor, TLR7 (Toll-like receptor 7). Activation of TLR7 by influenza also results in C3 (complement 3) release from platelets that leads to complement cascade activation and release of neutrophil DNA which can contribute to aggregates.
More than 60 genes have already been discovered as cause of an inherited platelet disorder (IPD). Many of these genes are widely expressed and are associated with broader clinical symptoms than causing solely a bleeding tendency. In this presentation examples will be discussed on how next generation sequencing has proven successful with its implementation in clinical diagnostics and gene discovery. Still at least half of the IPD patients receive no genetic diagnosis. Ideas will be put forward on how to tackle the challenges ahead that include discoveries in the non-coding genome space and setting up improved disease models for IPD that will allow (automated) deep phenotyping.
Functional disulfide bonds in hemostasis and thrombosis

Philip Hogg PhD

Traditional view of coagulation proteins
- a single disulfide-bonded or covalent form

New view
- multiple disulfide-bonded or covalent forms

Perturbation of the mix of the covalent forms of coagulation proteins could tip the balance between bleeding and clotting in individuals and underlie some hereditary or acquired thrombophilias.

For references, see Butera and Hogg\textsuperscript{24} Hogg\textsuperscript{25}.
Disparities in pregnancy outcomes: Differences by condition and community

Andra H. James MD

Maternal mortality per 100,000 live births

Global causes of maternal death

Blood donations per 1000 population by countries’ income: a measure of blood availability

Both the maternal and fetal outcomes of pregnancy vary according to a pregnant woman's community and her condition. The most devastating outcome is the death of a month. On 2017, there were approximately 295,000 maternal deaths with dramatic differences in maternal mortality based on the region of the world, the country, and women's underlying conditions. Worldwide, the leading cause of maternal death is hemorrhage. Ninety-nine percent of maternal deaths and 99% of those due to hemorrhage occur in low- or middle-income countries. Whether a hemorrhage originates from inside the uterus (80%), from laceration or incisions (20%), or from an underlying coagulopathy (less than 1%), and acute acquired coagulopathy will evolve unless the hemorrhage is not available, because besides the usual obstetric measures, blood, hemostatic medication and hematologic expertise are necessary to save mothers' lives.
Specificity of ADAMTS13 and regulation of ADAMTS13 function

Colin A. Kretz
Pregnancy, postpartum and periods: Current challenges in the management of women with Von Willebrand disease

Michelle Lavin MB, PhD, FRCPath

Challenges in the management of women with VWD

- **Periods**
  - Identifying & testing women with HMB
  - Objective measurement of menstrual loss
  - Best first-line therapies for women with VWD

- **Pregnancy**
  - Understanding pregnancy induced plasma VWF increase
  - Optimal plasma VWF target for delivery
  - Consistent approaches to neuraxial anaesthesia

- **Postpartum**
  - Secondary postpartum haemorrhage: Definition, prevention and early identification
  - Iron status in the postpartum
  - Future pregnancy planning

Women are disproportionately impacted by Von Willebrand disease (VWD) due to gynaecological bleeding. Heavy menstrual bleeding (HMB) is the most frequently reported and highest scoring bleeding symptom for women with VWD yet optimal treatment strategies remain uncertain. In pregnancy, there remains controversy regarding the ideal therapeutic plasma Von Willebrand factor (VWF) target at delivery. While thresholds similar to surgery are often utilized, this approach fails to account for the physiological pregnancy-induced increase in plasma Von Willebrand factor (VWF) levels, with median plasma VWF levels >200–250 IU/dl in healthy women at delivery. The limitations of current approaches for women with VWD are reflected in primary postpartum haemorrhage (PPH) rates, which remain increased even when replacement therapy is used.

Postpartum, as plasma VWF levels return, to baseline women with VWD are at a markedly increased risk of secondary PPH following discharge. As women with VWD may be normalized to HMB, recognition of secondary PPH may be delayed or missed.
The impact of aging and inflammation on plasma Von Willebrand factor levels

Frank W.G. Leebeek

1. VWF levels increase with aging in the general population and patients with type 1 VWD.

2. The age-related increase of VWF seems to be related to the incidence of endothelial dysfunction and atherosclerosis at an older age.

3. It is hypothesized that both increased release of VWF and reduced clearance of VWF contribute to the increase of levels with aging.

In the general population Von Willebrand factor (VWF) levels rise with aging, especially above the age of 40. As is shown in the figure, several mechanisms have been suggested to be responsible for this increase. This may be increased release of VWF from the endothelium, or decreased VWF clearance. Mechanisms contributing to increase of VWF are endothelial dysfunction, comorbidities (hypertension, diabetes), weight gain, atherosclerosis and inflammation. This age-related increase is also observed in patients with type 1 Von Willebrand disease (VWD) and may result in (near) normal levels in elderly VWD patients. It is still disputed whether this rise is associated with attenuation of the bleeding tendency. Results of an observational study on bleeding symptoms over one year have shown that bleeding was not reduced in type 1 VWD patients above the age of 65 compared to those <65 years, however prospective data are still lacking.
Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation

Weikai Li PhD

The catalytic cycle of vitamin K epoxide reductase (VKOR) and inhibition by vitamin K antagonists are accompanied with redox-state and conformation changes. The hemisphere (pink) and cylinder (grey) illustrate VKOR luminal and transmembrane domain, respectively. VKOR reduces vitamin K epoxide (KO) to quinone (K) and then to hydroquinone (KH2). A catalytic cysteine forms covalent and charge-transfer complex with KO and K, generating mercapto adducts of 3-hydroxyl K (S-KOH) and K (S-KH), respectively. Their binding induces a closed conformation that juxtaposes all cysteines (SH or S-S) for unimpeded electron transfer to reduce the mercapto adduct. VKOR becomes fully oxidized and changes to an open conformation that releases the reaction product. Warfarin competes with the substrates for the partially-oxidized enzyme. Unlike the substrates, warfarin binds also to the fully-oxidized enzyme and removes it from the enzyme pool. The bound warfarin locks HsVKOR in both redox states into a closed conformation.35-37
Pathogenic factor XII mutations: Form determines dysfunction

Coen Maas
During inflammation, platelets are activated and release extracellular vesicles (EVs). These EVs enter the bone marrow (BM), where they bind to resident BM cells including megakaryocytes (MKs). These plasma-originating EVs help communicate changes in the circulation directly into the BM, and may contribute to BM reprogramming during inflammation.
## Current and future haemophilia treatment options: Clinician perspective

**Michael Makris MD**

### HEMOPHILIA TREATMENTS

| Current | 2021 | Future |
|---------|------|--------|
| **Standard half-life** | • FVIII/FIX – Plasma/recombinant | **Extended half-life** | • Intravenous: FVIII-Fc+XTEN |
| **Extended half-life** | • FVIII- Fc, PEG | | • Subcutaneous: FVIII, FIX, FVIIa |
| **Bypassing agents** | • FIX- Fc, Albumin, PEG | **Bispecific antibodies** | • FIX/X mimetics |
| **Bispecific antibody** | • rFVIIa | | • Vs other molecules |
| **Activated PCC** | | **Rebalancing therapies** | • Antithrombin siRNA |
| | | | • Anti-TfPI |
| | | | • Anti-APC |
| | | **Gene therapy** | • AAV |
| | | | • Lentivirus |
| | | | • Lipid nanoparticles |
| | | **Shielded spheres** |
Cerebral venous sinus thrombosis

Ida Martinelli MD, PhD

Clinical suspicion of CVST
- Headache
- Motor deficit
- Seizure
- Visual loss/spilledema
- Mental disorder

Neuro-imaging

Unenhanced CT scan

Enhanced CT scan and/or MRI

Confirmed CVST

Treatment of the acute phase

Very severe presentation
Consider Endovascular treatment

Anticoagulation

Complications
Consider Concomitant treatments

Evaluation of risk factors

CVST with transient risk factor
9-6 months

CVST with unmodifiable risk factor
Long term

Abbreviations: CVST, cerebral venous sinus thrombosis; CT, computed tomography; MRI, magnetic resonance imaging
Fibrin(ogen)-endothelial cell interactions in inflammation

Leonid Medved, PhD

- Transendothelial migration of leukocytes is a key step in their recruitment to sites of inflammation.
- Fibrin(ogen) and its degradation products promote leukocyte transmigration and thereby inflammation by interacting with various endothelial cell receptors.
- Interaction of fibrin and its degradation product $E_1$ fragment with the endothelial VLDL receptor (VLDLR) and VE-cadherin occurs through fibrin $\beta$N-domains.
- Three pathways of fibrin(ogen)-dependent leukocyte transmigration have been proposed: 1. (Mac-1)-Fibrinogen-(ICAM-1)-dependent 2. (CD11c)-$E_1$ fragment-(VE-cadherin)-dependent 3. Fibrin-VLDL receptor-dependent

Two of the proposed fibrin(ogen)-dependent pathways of leukocyte transmigration are based on the bridging mechanism. The first one suggests that fibrinogen bridges leukocytes to the endothelium through the interaction with endothelial receptor ICAM-1 and leukocyte integrin Mac-1 to promote leukocyte transmigration\textsuperscript{41} (left panel). The second one suggests that fibrin degradation product $E_1$ fragment promotes leukocyte transmigration by bridging leukocytes to the endothelium through the interaction with endothelial VE-cadherin and leukocyte integrin CD11c (left panel), and the $\beta$15-42 fragment inhibits this interaction and thereby inflammation.\textsuperscript{42} Our studies revealed that interaction of fibrin with the endothelial VLDL receptor promotes transendothelial migration of leukocytes through the fibrin-VLDL receptor-dependent pathway (left panel), identified two monoclonal antibodies inhibiting this interaction, and clarified the molecular mechanism underlying this pathway and the inhibitory role of $\beta$15-42 in this pathway\textsuperscript{43} (right panel). These antibodies exhibited significant anti-inflammatory properties and may represent potential therapeutics for treatment of fibrin-dependent inflammation.
Fibrin(ogen) in human disease

Marguerite Neerman-Arbez PhD

| Fibrin(ogen)                      | Mechanism                                      | Consequence                      | Outcome                                     |
|----------------------------------|-----------------------------------------------|----------------------------------|---------------------------------------------|
| Mutations                        | Quantitative defects:                         | Bleeding, Thrombosis             |
|                                  | - low or absent fibrinogen                    |                                  |                                             |
|                                  | Qualitative defects:                         |                                  |                                             |
|                                  | - abnormal clot structure                    |                                  |                                             |
|                                  | Amyloidosis                                   |                                  |                                             |
| Inappropriate                     | Abnormal clot structure                       | Bleeding, Thrombosis             |
| post-translational                |                                               |                                  |                                             |
| modifications                    |                                               |                                  |                                             |
| High levels                      | Hypercoagulability,                           | CVD                              |
| (e.g. inflammation)              | metabolic dysfunction                         | Cancer: worse outcome            |
| Abnormal localisation             | Inflammation, demyelination                   | Neurological disease             |
| - in CNS                         | Amyloidosis                                   | Renal disease                    |
| - in kidney                      |                                               |                                  |                                             |
| Interaction with                 | Limits antimicrobial role of fibrinogen       | Microbial infections             |
| virulence factors                |                                               |                                  |                                             |
| Extra-hepatic                     | Increases cancer growth and invasive potential| Cancer: worse outcome            |
| expression (carcinoma)           |                                               |                                  |                                             |

With fibrin, produced by thrombin-mediated cleavage, fibrinogen plays important roles in many physiological processes.\textsuperscript{44,45} Formation of a stable blood clot, containing polymerised and cross-linked fibrin, is crucial to prevent blood loss and drive wound healing upon injury. Balance between clotting and fibrinolysis is essential. Several diseases are the consequence of altered levels of fibrinogen, others are related to structural properties of the molecule. Inflammation leads to elevated circulating levels of fibrinogen and hypercoagulability, a risk factor for cardiovascular disease (CVD). The source and localisation of fibrinogen also has clinical implications. Fibrinogen has been associated with cancer development and progression. While fibrinogen is implicated in defense against pathogens, in other settings it enhances bacterial virulence.
Markedly elevated plasma VWF:Ag levels and VWF propeptide levels are present in children with severe *Plasmodium falciparum* malaria, consistent with acute endothelial cell (EC) activation and Weibel Palade body (WPB) secretion. Higher VWF levels correlate with worse clinical outcomes. Pathological ultra-large (UL-) VWF multimers are also a feature of cerebral malaria. In vitro studies have demonstrated that UL-VWF strings on the surface of activated EC can recruit platelets. Subsequently, the platelet-decorated UL-VWF strings can then tether malaria-infected red blood cells (IRBC) under physiological shear stress. In particular, *P. falciparum* erythrocyte membrane protein-1 (PfEMP-1) on the IRBC interacts with platelet CD36. Collectively, these findings support the hypothesis that VWF plays role in regulating microvascular sequestration of IRBC in children with cerebral malaria.

Image created with BioRender.com.
Novel roles for Von Willebrand Factor in cancer progression

Angiogenesis
VWF sequesters growth factors within the circulation to promote angiogenesis and cell proliferation.

Coagulopathies
Marked VWF secretion, induced by tumour cells, serves to increase the risk of cancer-associated thrombosis.

Inflammation
VWF can recruit immune cells, mediate cytokine production and increase vascular permeability.

Metastasis
Tumour-induced endothelial activation triggers the release of VWF multimers which tether platelets and tumour cells, promoting migration and metastasis.

For reference, see Patmore et al\textsuperscript{69}
Pulmonary embolism in children

Madhvi Rajpurkar MD

Pulmonary Embolism in Children
Current knowledge and future perspectives
Madhvi Rajpurkar, MD

Epidemiology
- Increasing rate but infrequent at individual centers
- Two distinct patterns: In-situ pulmonary artery thrombosis and classic thrombo-embolic PE
- Highest risk in adolescent females
- African American 2.38 X higher rate

Clinical Prediction Rules
- Significant delay in time to diagnosis
- D-dimer often positive, but not discriminative
- Adult criteria (Wells, PERC etc.) have poor predictive values

Risk Stratification and prognosis
- Adult risk prediction models do not correlate well with outcomes
- High rate of thrombolysis
- Non-validated measures used for thrombolytic therapy

Duration of Therapy and Outcomes
- Pooled mortality reported is 26%
- Recurrent VTE rate is 5.5–19%
- Optimal duration unknown: KIDS-DOTT trial results pending
- Post-PE syndrome not defined

Future perspectives
- BEEP (Bedside Exclusion of Pulmonary Embolism in children without Radiation) study: PERC-Peds criteria to exclude PE
- FUVID study: Evaluate post-PE functional outcomes
- Setting up institutional pediatric PERTs

For references, see Biss et al, Carpenter et al, Rajpurkar et al
Intermolecular interactions that stabilize multimeric FXIII

Verena Schroeder PhD

**Intermolecular Interactions that Stabilize Multimeric FXIII**

What holds the A subunits together?

- The activation peptide, and in particular the sequence **FGGR**, stabilizes the FXIII A$_2$ dimer [1]

- Four intersubunit interactions located at the dimer interface stabilize the A$_2$ dimer [2]:
  - Arg11 - Asp343
  - Lys113 - Asp367
  - Lys257 - Glu401
  - Arg260 - Asp404

Domains of the A subunits: Activation peptide (AP), β-sandwich, core domain, β-barrel 1, β-barrel 2

What holds the A and B subunits together?

- In the B subunits, the N-terminal Sushi domains 1 and 2 are responsible for binding to the A subunits, stabilizing the FXIII A$_2$B$_2$ tetramer

- In the A subunits, β-barrel 1 and β-barrel 2 domains bind to the B subunits

Figures modified from [3] where also further references can be found

For references, see Handrkova et al.,$^{53}$ Li et al.,$^{54}$ Schroeder et al.$^{55}$
Factor VIII structure: Determinants of inhibitor development

Paul Clinton Spiegel, Jr. PhD

Hemophilia A is an X-linked bleeding disorder that affects 1 in 5,000 males worldwide due to a deficiency in blood coagulation factor VIII (fVIII), an essential protein for the proteolytic activation of factor X to Xa. Through the past 20 years, the structure and function of fVIII has come into focus. New atomic-level structural findings illustrate a detailed domain organization of fVIII structure, \(^5^6\) novel localized and domain-scale conformational changes, the molecular nature of the fVIII/Von Willebrand factor complex, and pathogenic antibody epitopes. \(^5^7^5^8\) Further structural characterization of fVIII circulatory complexes will uncover the fundamental basis for its procoagulant cofactor function and may aid in next-generation bioengineering efforts to improve fVIII stability and circulatory half-life while minimizing its immunogenicity. These efforts may prove vital for both fVIII replacement and gene therapy approaches.
Do platelet transfusions work?

S.J. Stanworth and Laura Green

Benefits of platelet transfusion:
• Decreased risk of bleeding
• Decreased complications/organ dysfunction
• But variable/limited efficacy e.g., cold-stored platelets, autologous transplantation

Harm of platelet transfusions:
• Mortality
• Long-term recovery
• Transfusion reactions (platelets most commonly implicated blood component)

A number of randomised trials have evaluated the risk-benefit ratio for platelet transfusion for prophylaxis and treatment of major bleeding. Trials in some settings have indicated evidence of harm with more ‘liberal’ use of platelets, although a benefit to improve outcomes has also been found in major bleeding. Our understanding of donor, storage and processing characteristics on outcomes following platelet transfusion have been inadequately investigated. We need a better understanding of how platelet transfusions affect both haemostasis and inflammation in patients, to indicate which patients really require platelet transfusions.
Fibrin clot structure characterized by fiber diameter and pore size differs between healthy persons and patients with thromboembolic diseases. Prothrombotic fibrin clot phenotype is associated with faster formation of denser fibrin mesh, relatively resistant to lysis, as reflected by prolonged clot lysis time (CLT). Increased plasma fibrin clot density has been reported in patients with prior or acute thromboembolic events.
WA has received grant funding from Bayer and payments from Bayer, Portola, Aspen, Sanofi, BMS/Pfizer, Daiichi Sankyo; MC has received grant funding from Leo Pharma, Pfizer, BMS and consulting fees from Leo Pharma, Pfizer, Bayer, BMS, Servier, Sanofi; ACC has received funding from the American Heart Association; PC has received grant funding from CSL Behring. Werfen (TEM International), Haemonetics, the Welsh Government and personal fees from CSL Behring, Werfen; JEF has received funding from the American Heart Association; KF has received funding from Sobi (Swedish Orphan Biovitrum); ML has received consulting fees from Sobi, Treseum Pharmaceuticals, Takeda; FWGL has received grant funding from CSL Behring, Takeda/Baxalta, uniQure, SOBI and consulting fees from CSL Behring, Biomarin, Takeda, UniQure; KM has received funding from the American Society of Hematology, NIH and consulting fees from STRM.BIO; MM has received grants from Bayer, BPL, CSL Behring, Kedrion, NovoNordisk, Octapharma, Pfizer, Roche, Sobi, Takeda and consulting fees from Novo Nordisk, Grifols, Sanofi; LM has received funding from the NIH; JO has received grant funding from LEO Pharma; VS has received funding from the Swiss National Science Foundation; all other authors declare no conflicts of interest.

REFERENCES

1. Di Nisio M, Valeriani E, Riva N, Schulman S, Beyer-Westendorf J, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis. J Thromb Haemost. 2020;18:1562-1568. https://doi.org/10.1111/jth.14836.

2. Wang J, Ren D, Liu Y, et al. Effects of early mobilization on the prognosis of critically ill patients: A systematic review and meta-analysis. Int J Nurs Stud. 2020;110:103708.

3. Ge X, Cavallazzi R, Li C, et al. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Chochrane Database Syst Rev. 2012;CD004084.

4. Alhazzani W, Lim W, Jaeschke RZ, et al. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41:2088-2098.

5. Wang Y, Huang M, Liang Z. Can intermittent pneumatic compression reduce the incidence of venous thrombosis in critically ill patients: A systematic review and meta-analysis. Clin Appl Thromb (Hameost. 2020;26:1076029629913942.

6. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.

7. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881.

8. De Stefano V, Rossi E, Carobbio A, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8(11):112.

9. Samuelsson E, Hägg S. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet Gynecol Scand. 2004;83(7):674-681.

10. Scheres LJJ, van Hylckama VA, Ballieux BEPB, et al. Endogenous sex hormones and risk of venous thromboembolism in young women. J Thromb Haemost. 2019;17(8):1297-1304.

11. Roach RE, LiFering WM, Rosendaal FR, Cannegieter SC, le Cessie S. Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation. 2014;129(1):51-56.

12. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974.

13. Holmes CE, Ades S, Gilchrist S, et al. Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic. JCO Oncol Pract. 2020;16(9):e868-e874.

14. Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci U S A. 2009;106(33):13939-13944.

15. Cleuren ACA, van der Ent MA, Jiang H, et al. The in vivo endothelial cell translatome is highly heterogeneous across vascular beds. Proc Natl Acad Sci U S A. 2019;116(47):23618-23624.

16. Collins PW, Bell SF, de Lloyd L, Collins RE. Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. Int J Obstetric Anesthesia. 2018;37:106-117.

17. Collins PW, Lilley G, Bruynseels D, et al. Fibrinogen-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood. 2014;124:1727-1736.

18. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometric-guided early fibrinogen concentration replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J Anaesth. 2017;119:411-421.

19. Carminita E, Panicot-Dubois L, Dubois C. DNAse-dependent but NETs-independent pathway of thrombus formation in vivo. Res Pract Thromb Haemost. 3(Suppl 1):1-891. https://doi.org/10.1016/S0049-3848(20)30407-2.

20. Palacios-Acedo AL, Mege D, Crescence L, Panicot-Dubois L, Dubois C. Cancer animal models in thrombosis research. Thromb Res. 2020;20191(Suppl 1):S112-S116. https://doi.org/10.1016/S0049-3848(20)30407-2.

21. Megy K, Downes K, Simeoni I, et al. Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2019;17:1253-1260.

22. Ver Donck F, Downes K, Freson K. Strengths and limitations of high-throughput sequencing for the diagnosis of inherited bleeding and platelet disorders. J Thromb Haemost. 2020;18:1839-1845.
23. Turro E, Astle WJ, Megy K, et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature. 2020;583(7814):96-102.

24. Butera D, Hogg PJ. Fibrinogen function achieved through multiple covalent states. Nat Commun. 2020;11(1):5468.

25. Hogg PJ. Multiple disulphide-bonded states of native proteins: Estimate of number using probabilities of disulphide bond formation. Molecules. 2020;25(23).

26. WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Maternal mortality: Levels and trends. Geneva, CH; 2019:104.

27. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323-e333.

28. James AH, McIntock C, Lockhart E. Postpartum hemorrhage: when uterotonic and sutures fail. Am J Hematol. 2012;87(Suppl 1):S16-S22.

29. Lavin M, Aguila S, Dalton N, et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784-1791. https://doi.org/10.1182/bloodadvances.2018017418.

30. James AH, Konkle BA, Kourides P, et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia. 2015;21(1):81-87. https://doi.org/10.1111/hae.12568.

31. Stoof SCM, van Steenbergen HW, Zwagemaker A, et al. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia. 2015;21(4):505-512. https://doi.org/10.1111/hae.12635.

32. Biguzzi E, Castelli F, LJifering WM, et al. Rise of levels of von Willebrand factor and factor VIII with age: role of genetic and acquired risk factors. Thromb Res. 2021;197:172-178.

33. Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018;132(2):141-147.

34. Sanders YV, Giezenaar MA, Laros-van Gorkom BAP, et al. Von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost. 2014;12(7):1066-1075.

35. Liu S, Li S, Chen G, Sukumar N, Krezel AM, Li W. Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation. Science. 2021;371(6524):eabc5667.

36. Li S, Liu S, Liu XR, Zhang MM, Li W. Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy. Blood Adv. 2020;4:2202-2212.

37. Shen G, Cui W, Zhang H, et al. Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer. Nat Struct Mol Biol. 2017;24:69-76.

38. Clark CC, Hofman ZLM, Sanrattana W, et al. The fibronecetin type II domain of factor XII ensures zymogen quiescence. Thromb Haemost. 2020;120(3):400-411.

39. Scheffel J, Mahnke NA, Hofman ZLM, et al. Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. Nat Commun. 2020;11:179.

40. Hofman ZLM, Clark CC, Sanrattana W, et al. A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation. J Biol Chem. 2020;295(2):363-374.

41. Altieri DC. Regulation of leukocyte-endothelium interaction by fibrinogen. Thromb Haemost. 1999;82:781-786.

42. Petzelbauer P, Zacharowski PA, Miyazaki Y, et al. The fibrin-derived peptide Bβ15–42 protects the myocardium against ischemia-reperfusion injury. Nat Med. 2005;11:298-304.

43. Yakovlev S, Cao C, Galisteo R, Zhang L, Strickland DK, Medved L. (2019) Fibrin-VLDL receptor-dependent pathway promotes leukocyte transmigration by inhibiting Src kinase Fyn and is a target for fibrin β15–42 peptide. Thromb Haemost. 2019;119:1816-1826.

44. Vilar, Fish, Casini and Neerman-Arbez. Haematologica. 2020.

45. Wolberg and Pieters. RPTH 2019.

46. O’Sullivan JM, Preston RJ, O’Regan N, O’Donnell JS. Emerging roles for hemostatic dysfunction in malaria pathogenesis. Blood. 2016;127(19):2281-2288.

47. O’Regan N. Gegenbauer K, O’Sullivan JM, et al. A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. Blood. 2016;127(9):1192-1201.

48. Bridges DJ, Bunn J, van Mourik JA, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood. 2010;115(7):1472-1474.

49. Patmore S, Dhami SPS, O’Sullivan JM. Von Willebrand factor and cancer; metastasis and coagulopathies. J Thromb Haemost. 2020;18(10):2444-2456.

50. Biss T, Rajpurkar M, Williams S, van Ommen C h, Chan A k c, Goldenberg N a. Recommendations for future research in relation to pediatric pulmonary embolism: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(2):405-408.

51. Carpenter SL, Richardson T, Hall M. Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014. Blood Adv. 2018;2:1403-1408.

52. Rajpurkar M, Biss TT, Amankwah EK, et al. Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. Thromb Haemost. 2017;117:1199-1207.

53. Handrкова H, Schroeder V, Kohler HP. The activation peptide of coagulation factor XIII is vital for its expression and stability. J Thromb Haemost. 2015;13:1449-1458.

54. Li B, Kohler HP, Schroeder V. Identification of amino acid residues that are crucial for FXIII-A intersubunit interactions and stability. Blood. 2020;135:145-152.

55. Schroeder V, Kohler HP. Factor XIII, structure and function. Semin Thromb Hemost. 2016;42:422-428.

56. Smith IW, d’Aquino AE, Coyle CW, et al. The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain. J Thromb Haemost. 2020;18:57-69.

57. Walter JD, Werther RA, Brison CM, et al. Structure of the factor VIII C2 domain in ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes. Blood. 2013;122:4270-8.

58. Gish JS, Jarvis L, Childers KC, et al. Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor. Blood. 2021;137:2981-2986.

59. Curley A, Stanworth SJ, Willoughby K, et al. Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med. 2019;380(3):242-251.

60. Cardenas JC, Zhang X, Fox EE, et al. Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPRP trial. Blood Adv. 2018;2(14):1696-1704. https://doi.org/10.1182/bloodadvances.2018017699.

61. Tružli DJ, Assmann SF, Strauss RG, et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood. 2012;119(23):5553-5562.

How to cite this article: Krishnaswamy S, Ageno W, Arabi Y, et al. Illustrated State-of-the-Art Capsules of the ISTH 2021 Congress. Res Pract Thromb Haemost. 2021;5:e12532. https://doi.org/10.1002/rth2.12532.